Aminocaproic acid (aminocaproic acid) tablets 0.5 №20

Aminocaproic acid (aminocaproic acid) tablets 0.5 №20

$7.00

Manufacturer: Ukraine

Prevention and treatment of parenchymal bleeding, hemorrhages from mucous membranes, menorrhagia, bleeding from erosions and ulcers of the stomach and intestines. Prevention of bleeding during operations on the liver, lungs, pancreas. Various types of hyperfibrinolysis, including those associated with the use of thrombolytic drugs and massive transfusion of canned blood. As a symptomatic remedy – bleeding due to thrombocytopenia and qualitative inferiority of platelets (dysfunctional thrombocytopenia).

Category:

Description

Ingredients

active ingredient: aminocaproic acid;

1 tablet contains aminocaproic acid 500 mg;

excipients: anhydrous colloidal silicon dioxide, povidone (polyvinylpyrrolidone), croscarmellose sodium, magnesium stearate.

Pharmacotherapeutic group

Antihemorrhagic agents. fibrinolysis inhibitors. ATX code B02A A01.

Pharmacodynamics

Aminocaproic acid inhibits fibrinolysis in the blood and tissues. By blocking plasminogen activators and partially suppressing the action of plasmin, it has a specific hemostatic effect in bleeding associated with an increase in fibrinolysis. In addition, aminocaproic acid inhibits the action of streptokinase, urokinase and tissue kinases, which consists in the activation of fibrinolysis; neutralizes the effects of kallikrein, trypsin, hyaluronidase, reduces capillary permeability, inhibits the formation of antibodies. Due to the inhibition of fibrinolysis, it has a wide range of pharmacological actions, including immunosuppressive, anti-inflammatory and anti-allergic activity, which provides a high therapeutic effect in various diseases accompanied by activation of fibrinolysis.

Aminocaproic acid inhibits the pathological proteolytic activity caused by the action of the influenza virus, inhibits the processes of virus separation, acting on the early stages of the interaction of the virus with a sensitive cell. Improves some cellular and humoral indicators of specific and non-specific protection in respiratory viral infections. The drug has low toxicity.

Indications

Prevention and treatment of parenchymal bleeding, hemorrhages from mucous membranes, menorrhagia, bleeding from erosions and ulcers of the stomach and intestines. Prevention of bleeding during operations on the liver, lungs, pancreas. Various types of hyperfibrinolysis, including those associated with the use of thrombolytic drugs and massive transfusion of canned blood. As a symptomatic remedy – bleeding due to thrombocytopenia and qualitative inferiority of platelets (dysfunctional thrombocytopenia).

Contraindications

Increased individual sensitivity to the drug, a tendency to thrombosis and thromboembolic diseases, disseminated intravascular coagulation syndrome, gross hematuria, kidney disease with impaired function, renal failure, hematuria, severe coronary heart disease, cerebrovascular accident.

Directions

Aminocaproic acid tablets are administered orally. Divide the daily dose for adults into 3-6 doses, for children – for 3-5 doses.

Moderately pronounced increase in fibrinolytic activity of the blood. Adults are usually prescribed in a daily dose of 5-24 g (10-48 tablets).

The daily dose for children aged 3-6 years is 3-6 g (6-12 tablets), 7-10 years – 6-9 g
(12-18 tablets). For adolescents, the maximum daily dose is 10-15 g (20-30 tablets).

Acute bleeding (with increased fibrinolytic activity, including gastrointestinal bleeding). A single dose of the drug for adults is 5 g (10 tablets) during the first hour of treatment, followed by 1-2 g (2-4 tablets) hourly for 8 hours or until bleeding stops. Daily dose for children with acute blood loss: 3-4 years old – 6-9 g (12-18 tablets), 5-8 years old – 9-12 g (18-24 tablets), 9-10 years old – 18 g (36 tablets ).

Traumatic hyphema. Assign at a dose of 0.1 g/kg of body weight every 4 hours (but not more than
24 g/day) for 5 days.

Metrorrhagia associated with intrauterine contraceptives. Assign 3 g (6 tablets) every 6 hours.

Prevention and control of bleeding during dental interventions. Adults appoint 2-3 g (4-6 tablets) 3-5 times a day.

For adults, the average daily dose is 10-18 g (20-36 tablets), the maximum daily dose is 24 g (48 tablets). The course of treatment is 3-14 days.

For children under 3 years of age, the drug should be prescribed in a different dosage form.

In conditions accompanied by various types of hyperfibrinolysis, the duration of oral administration of aminocaproic acid depends on the clinical picture and the severity of the disease and is determined by the doctor individually. A single dose with repeated use depends on the state of the blood coagulation system. The doctor can adjust the dose and prescribe a second course of treatment.

Related products